Showing 191-200 of 219 results for "".
- Allergan Buys Luminera Dermal-Filler Businesshttps://modernaesthetics.com/news/allergan-buys-luminera-dermal-filler-business/2473000/Allergan Aesthetics, an AbbVie company, has acquired Luminera's full dermal filler portfolio and R&D pipeline. Luminera is a privately held aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. "
- Dr. Roy Geronemus Awarded the Vic Narurkar, MD Innovations in Aesthetic Dermatology Lectureship Awardhttps://modernaesthetics.com/news/dr-roy-geronemus-awarded-the-vic-narurkar-md-innovations-in-aesthetic-dermatology-lectureship-award-1/2472843/Roy Geronemus, MD of Laser & Skin Surgery Center of New York received, The American Society for Dermatologic Surgery inaugural Vic Narurkar, M.D., Innovations in Aesthetic Dermatology Lectureship Award Dr. Geronemus received the award at the 2019 ASDS annual meeting in Chicago. He d
- Neothetics, Inc.'s Stock Tumbles Following "Unambiguous" Negative LIPO-202 Resultshttps://modernaesthetics.com/news/neothetics-incs-stock-tumbles-following-unambiguous-negative-lipo-202-results/2472217/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares d
- Nearly 10.5 Million Treatments Performed by ASDS Members in 2016https://modernaesthetics.com/news/nearly-105-million-treatments-performed-by-asds-members-in-2016/2472226/Dermatologic surgeons performed nearly 10.5 million medically necessary and cosmetic procedures in 2016 – five percent more than 2015 and up 31 percent since 2012, according to the 2016 American Society for Dermatologic Surgery (ASDS) Survey on D
- Allergan Launches Juvéderm Volitehttps://modernaesthetics.com/news/allergan-launches-juvderm-volite/2472287/Allergan plc launched Juvéderm Volite, an injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session. This innovative new Allergan product uses the unique patented Vycross technology. The new HA injectable treatment d
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laserhttps://modernaesthetics.com/news/aad-2026-acclaro-to-highlight-expanding-clinical-uses-of-ultraclear-2910-nm-fiber-laser/2486381/Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber lase
- Murad Alam, MD, FAAD, Elected American Academy of Dermatology President for 2026https://modernaesthetics.com/news/murad-alam-md-faad-elected-american-academy-of-dermatology-president-for-2026/2473558/Chicago-based board-certified dermatologist Murad Alam, MD, FAAD, has been elected to lead the American Academy of Dermatology (AAD). He will be installed as president-elect in March 2025 and hold the office of president for 1 year beginning in March 2026. AAD is the world’s large
- Kenvue to Showcase 22 New Sets of Clinical Data at AADhttps://modernaesthetics.com/news/kenvue-to-showcase-22-new-sets-of-clinical-data-at-aad/2473552/Kenvue announced it will share 22 data sets detailing new Kenvue skin science research at the American Academy of Dermatology (AAD) Association annual meeting, March 8-12, in San Diego. Evidence will be presented on the clinical effectiveness of Neutrogena and Aveeno
- Hugel Resubmits BLA for Botulaxhttps://modernaesthetics.com/news/hugel-resubmits-bla-for-botulax/2473314/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i